Riken Vitamin Co., Ltd. Overview
| Item | Detail | Source |
|---|---|---|
| Legal name | 理研ビタミン株式会社 / RIKEN VITAMIN CO., LTD. | YUHO-FY26 cover |
| Former names | Riken Vitamin Oil Co., Ltd. (理研ビタミン油株式会社), from 1949 to January 1980 | YUHO-FY26 history |
| Corporate lineage | Traces to RIKEN (the Institute of Physical and Chemical Research, founded 1917) via predecessor Riken Eiyo Yakuhin (1938). The vitamin division personnel spun out in 1949. | YUHO-FY26 |
| Founding / incorporation | 27 August 1949, with capital of ¥3 million | YUHO-FY26; company IR deck Jan 2023 |
| Incorporation jurisdiction | Japan (Companies Act) | YUHO-FY26 |
| Corporate structure | Company with an Audit & Supervisory Committee (監査等委員会設置会社), adopted June 2017 | YUHO-FY26 |
| Headquarters | 1-6-1 Yotsuya, Shinjuku-ku, Tokyo, Japan. Relocated from Chiyoda-ku in November 2020. | YUHO-FY26 |
| Exchange / ticker | Tokyo Stock Exchange Prime Market: 4526. Listed October 1961 (2nd Section), moved to 1st Section December 2014, Prime from April 2022. | YUHO-FY26 |
| ISIN / CUSIP | confirm via JPX. CUSIP not applicable (no US listing or ADR identified). | — |
| Fiscal year end | 31 March | TANSHIN-FY26 |
| Share capital | ¥2,537 million | YUHO-FY26 |
| Shares issued | 30,705,100 at 31 Mar 2026. Treasury shares were 1,517,289, including 187,988 held in BIP/ESOP trusts. | TANSHIN-FY26 |
| Employees (consolidated) | 1,887 at 31 Mar 2026, plus 453 average temporary staff | YUHO-FY26 |
| Employees (parent) | 1,016; average age 39.5; average tenure 15.5 years; average salary ¥8.41 million | YUHO-FY26 |
| Auditor | KPMG AZSA LLC (有限責任 あずさ監査法人), 20 consecutive years. Audit fee FY2026: ¥122 million. | YUHO-FY26 |
| Market capitalisation | ≈¥102.1 billion on issued-share basis at ¥3,325 (28 Sep 2026, kabuyoho). ≈¥95 billion excluding treasury shares (analyst estimate). | kabuyoho; analyst calc |
| Group composition | Parent plus 18 subsidiaries: 14 consolidated (4 domestic, 10 overseas) and 4 non-consolidated | YUHO-FY26 |
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Employees consolidated (persons) | 1,825 | 1,848 | 1,857 | 1,858 | 1,887 |
| Employees parent (persons) | 958 | 957 | 966 | 997 | 1,016 |
| Temporary staff consolidated avg (persons) | 419 | 430 | 438 | 451 | 453 |
Source: YUHO-FY26, five-year summary.
Riken Vitamin is a mid-cap Japanese ingredients-and-foods maker whose identity comes from RIKEN's natural vitamin-A extraction work. Its core competence is extracting, purifying, concentrating and molecularly distilling natural raw materials, especially vegetable oils, seaweed, fish and plant pigments.
Consumers know it for "Fueru Wakame-chan" dried wakame, wakame soup and "Riken Non-Oil" dressings. Yet most sales and profit come from business-to-business products:
-
food-improving agents (emulsifiers such as distilled monoglycerides);
-
natural vitamin E antioxidants;
-
natural colours;
-
functional health ingredients;
-
seasonings and extracts;
-
polymer additives (anti-fog, anti-static, lubricant and plasticiser agents).
Overseas sales are about a quarter of the group, anchored by a core emulsifier plant in Malaysia. Management targets 35% overseas sales and ¥13.5 billion operating profit by the year ending March 2035.
The equity story combines three things: a cash-rich, low-leverage balance sheet; rising shareholder returns (a payout floor of 40% or more plus buybacks); and an ongoing unwinding of cross-shareholdings. It is constrained by low expected growth, which leaves the stock at about 1x P/B.
Company's own description
The annual report frames the group around the founding policy of "effective utilisation of natural resources" (天然物の有効利用). It describes a group that uses proprietary technology and development capability to create products in foods, food-improving agents, chemical-improving agents and vitamins, and supplies them in Japan and worldwide.
The stated management philosophy has five pillars:
-
Contributing to healthy, rich diets through food.
-
Compliance-based business conduct.
-
A flexible, creative manufacturer that uses its own "production seeds" (raw materials, technologies and equipment).
-
Building a "Riken Vitamin of the world" brand overseas.
-
A respectful, attractive workplace.
Source: YUHO-FY26, section 1.
The long-term vision is "to become a company that grows by supporting a sustainable society with specialty products and services" (持続可能な社会をスペシャリティな製品とサービスで支え、成長する会社になる). The goal year was moved from the company's FY2030 to its FY2034 in May 2025. Source: MTP2027.
Reporting structure versus product structure
Riken Vitamin reports three geographically defined segments:
Domestic Food Business: household foods, commercial foods, and processed-food ingredients including food-improving agents and vitamins.
Domestic Chemical & Other Business: chemical-improving agents and feed additives or feed oils.
Overseas Business: food-improving agents, chemical-improving agents, extracts and seasonings.
Internally, and in investor presentations, management also describes the business by product field:
Foods: extracts and seasonings, seaweed.
Improving agents: emulsifiers, antioxidant-grade vitamins, colours.
Healthcare: nutritional-fortification vitamins, functional food ingredients, microcapsules.
Other: All vitamins are booked to Healthcare, because sales cannot be split by end use. Source: company IR deck, 9 Jan 2026.
Business model and revenue model
| Engine | Customers | Economics | Indicative scale (FY2026) |
|---|---|---|---|
| Branded consumer foods (household) | Supermarkets, drugstores and e-commerce, via wholesalers | Brand-driven; high promotion and advertising intensity; volume-sensitive to price increases | ¥13,650 million (13.9% of gross segment sales) |
| B2B foods and food solutions (commercial plus processed-food ingredients) | Processed-food manufacturers, convenience-store vendors, foodservice, school and industrial catering, bakeries, noodle makers | Specification-driven; application centres support co-development; price revisions lag input costs | ¥52,710 million (53.8%) |
| Industrial / chemical additives and overseas ingredients | Plastics converters, packaging-film makers, agricultural-film makers, rubber, cosmetics, feed; global food manufacturers | Commodity-plus-specialty mix; exposed to palm and vegetable-oil pricing and to competition from Western and Chinese emulsifier makers | ¥31,579 million (Domestic Chemical plus Overseas, gross) |
Riken Vitamin is a manufacturer whose revenue is almost entirely product sales recognised at a point in time. The annual report confirms that all FY2025 and FY2026 revenue is "goods transferred at a point in time", with no over-time revenue. There is no material subscription, licensing or service revenue.
Revenue is reduced by rebates and promotional allowances to distributors and retailers. These rebates are a critical accounting estimate: accrued promotion expenses were ¥636 million at FY2026 year-end. Source: YUHO-FY26 and TANSHIN-FY26 notes.
The model has three distinct economic engines:
Source: TANSHIN-FY26 segment breakdown; analyst grouping.
Value-chain position
Riken Vitamin sits mid-stream. It buys imported vegetable oils and palm derivatives, mainly through trading houses and oil refiners. It buys aquacultured wakame from Sanriku (Iwate and Miyagi), gardenia fruit and other botanicals, and animal-derived raw materials such as pork for extracts made in Oklahoma.
It converts these by distillation, esterification, extraction and blending into:
-
ingredients sold to food and chemical manufacturers; and
-
branded packaged foods sold through distribution.
It is also vertically integrated upstream in seaweed. Through subsidiary Riken Foods it runs wakame seedling development at "Yuriage Factory" in Natori, Miyagi (opened 2017), and land-based green-laver (スジアオノリ) aquaculture at "Rikuzentakata Base" in Iwate (opened October 2021). Source: YUHO-FY26 R&D section.
Independent characterisation
Riken Vitamin is best understood as a Japanese specialty lipid-chemistry and natural-extract company that happens to own a strong consumer brand franchise. The consumer image of "dressings and wakame" understates the B2B core, a point made explicitly by outside director Shinichi Hirano in the 2023 integrated report.
Key characteristics:
-
Profitability is moderate (operating margin 7–10% over FY2022–FY2026). It is constrained by domestic demographic decline, input-cost volatility and commoditisation of emulsifiers overseas.
-
The balance sheet is a defining feature: an equity ratio of about 72%, net cash, and ¥15 billion of investment securities.
-
The investment case therefore depends heavily on capital allocation (buybacks, cross-shareholding unwind, payout) as much as on operations.
-
The 2020 Qingdao accounting scandal is a governance legacy that shaped the current subsidiary-control framework and still colours investor perception.
Strategy
Stated strategy themes (MTP2027 and YUHO-FY26)
Riken Vitamin's long-term vision is to become a company that grows by supporting a sustainable society with specialty products and services. The goal year was reset in May 2025 to the year ending March 2035.
FY2035 quantitative goals (company "FY2034"):
-
Operating profit ¥13.5 billion.
-
Overseas sales ratio 35%, up from 25% in FY2025.
-
ROE of 10–12%.
MTP2027 (April 2025 – March 2028) is framed as three years of "aggressive capital investment and restructuring of the business framework in anticipation of demographic change". It combines:
-
Strengthening domestic earnings sustainability:
-
Grow slightly faster than the processed-food market.
-
Invest in productivity and labour-saving automation at ageing plants.
-
Household: market-creating products and revitalising existing brands.
-
Commercial: ready-meal ("nakashoku/sokushoku") demand and labour-shortage-driven new markets.
-
Processed-food ingredients: substitutes for unstable raw materials, production-efficiency and food-loss solutions, and health markets.
-
Chemicals: concentrate on strength areas (lubricants, anti-fog agents, plasticisers, anti-static agents); expand biomass-based products; partner in non-core areas; support Japanese customers expanding abroad.
-
-
Building a new overseas framework for a leap forward:
-
Front-load investment for specialty-product market expansion, concentrated on Rikevita Malaysia.
-
Break down domestic/overseas silos in production, sales, development and administration.
-
Restructure Chinese production lines and ramp the new Tianjin plant.
-
Build sales bases in each Southeast Asian country.
-
Use application centres for bakery.
-
Expand pork-extract capacity in the US.
-
-
Shift to balance-sheet- and share-price-conscious management: an explicit TSE "cost of capital" response.
-
Non-financial strategy: long-term R&D aimed at social issues; a new HR system based on the January 2025 "talent policy"; strengthened group governance.
MTP2027 targets and progress
| KPI | FY2025 actual (base) | FY2026 actual | FY2028 target (company "FY2027") |
|---|---|---|---|
| Net sales | ¥95.5bn | ¥96.3bn | ¥110.0bn |
| Operating profit (margin) | ¥8.7bn (9.1%) | ¥6.9bn (7.2%) | ¥10.0bn (9.1%) |
| EBITDA | ¥11.9bn | ¥11.5bn | ¥14.2bn |
| ROE | 12.1% | 8.7% | ≥10% |
| Payout ratio | 30.3% | 46.2% | ≥40% |
| Equity ratio | 70.1% | 71.6% | 60–65% |
| Cross-shareholdings / net assets | 19.0% | 17.9% | <10% |
| Segment | Sales | Operating profit |
|---|---|---|
| Domestic Food | ¥71.9bn | ¥7.5bn |
| Domestic Chemical | ¥9.7bn | ¥0.9bn |
| Overseas | ¥30.0bn | ¥1.6bn |
| Cash in | Cash out |
|---|---|
| Operating cash flow ¥28.0bn | Capex ¥25.0bn, 2.5x the prior plan (domestic ¥13.0bn, overseas ¥12.0bn; by field: improvers ¥15.2bn, foods ¥7.1bn, healthcare ¥1.9bn, other ¥0.8bn) |
| Cross-shareholding sales ¥9.0bn | Shareholder returns of ¥12.4bn or more |
| Plus cash and debt | Strategic investment (alliances, M&A, new businesses), with debt used if needed |
FX assumption: ¥150/$. Sources: MTP2027; COC-2026.
Cash allocation over three years:
Target market value: "first, ¥100 billion market capitalisation and P/B consistently above 1x" (COC-2026). On an issued-share basis this was achieved around September 2026, at about ¥102 billion.
Progress assessment after year one:
-
Sales are tracking (FY2027 guidance is ¥100 billion).
-
Profitability is materially behind. Reaching ¥10 billion operating profit requires about +40% from the FY2027 guidance of ¥7.1 billion in one year, which looks unlikely without a sharp overseas recovery.
-
The FY2026 single-year plan (sales ¥100 billion, OP ¥8.5 billion, NP ¥8.2 billion, EBITDA ¥12.0 billion) was missed on every line (YUHO-FY26).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Southeast Asian sales subsidiaries | Jan–Apr 2025 | Vietnam and Thailand entities; consolidated from 31 Mar 2026 |
| Talent policy | Jan 2025 | New HR philosophy: "respect individuality and raise each other; think and act autonomously". Talent portfolio of global, innovation, DX and management talent. |
| MTP2027 and vision reset | May 2025 | See above |
| Leadership transition | Jun 2025 | Mochizuki becomes President |
| Soka renewable-energy upgrade | Apr 2025 | 100 kW solar plus 200 kWh lithium-ion storage (Saitama Prefecture credit PR document) |
| Patto Jutto and Kakechae Ethnic launches | Mar 2025; Feb 2026 | Category-creating household products |
| China rationalisation | FY2026 | Commodity chemical lines in China stopped; staff shifted to the new food-improver plant |
| English simultaneous disclosure of full tanshin | From FY2026 results | IR enhancement (COC-2026) |
| Cost-of-capital framework | Jun 2025 and Jun 2026 | Cost of equity estimated at 8–9% (CAPM 6.6% plus investor hearings) |
| Guymon expansion | Dec 2023 – Aug 2027 | ¥1.54 billion for +500 t pork-extract capacity |
| US subsidiary relocation to Texas | Announced Jun 2026 | Expanded application centre and Ramen Lab |
| Anpachi (Gifu) new plant | Jun–Jul 2026 | ¥3.6 billion land purchase; replaces the Kyoto colours plant; supports gardenia-blue demand after the 2025 FDA approval |
| Shareholder returns | 2025–2026 | Payout floor raised to 40%; ¥2 billion buyback in each of FY2026 and FY2027 |
| Cross-shareholding unwind | FY2026 | ¥3.38 billion sold across 16 issues; Nomura, Riken Technos and Sumitomo Pharma fully exited; Itochu Shokuhin tendered in TOB |
Management guidance
| Item | H1 | Full year |
|---|---|---|
| Net sales | ¥49.5bn | ¥100.0bn (+3.8%) |
| Operating profit | ¥3.6bn | ¥7.1bn (+2.9%) |
| Ordinary profit | ¥3.8bn | ¥7.6bn (−1.4%) |
| Net profit | ¥2.9bn | ¥7.5bn (+6.6%) |
| EPS | — | ¥256.96 |
| DPS | — | ¥110 (payout 42.8%) |
| ROE | — | 9.0% |
| Segment | Sales | Operating profit |
|---|---|---|
| Domestic Food | ¥67.2bn | ¥6.44bn |
| Domestic Chemical | ¥9.0bn | ¥0.86bn |
| Overseas | ¥25.8bn | ¥0.2bn loss |
FY2027 guidance (13 May 2026, unchanged on 7 Aug 2026):
Segment guidance for the full year:
Source: SUPP-1Q27.
Products & Services
Sources: YUHO-FY26 business and R&D sections, TANSHIN-FY26 commentary, Integrated Report 2024, company IR decks (Jun 2025, Sep 2025, Jan 2026). Pricing is not disclosed for any product, so the pricing model column is omitted; consumer items are sold through retail at retailer-set prices. "Launch" is the original launch year where disclosed.
Domestic Food Business — Household Food
| Product / brand | Description and capabilities | Target customer | Launch / latest |
|---|---|---|---|
| Fueru Wakame-chan® (ふえるわかめちゃん) | Curled dried cut wakame that rehydrates and expands. The company claims No.1 share in domestic dried cut wakame. 50th-anniversary design renewal in 2026. | Households | 1976; renewal 2026 |
| Wakame Soup (わかめスープ) | Instant wakame soup. The company claims No.1 share in instant wakame soup. 45th anniversary in 2026. | Households | c.1981; renewal 2026 |
| Furikakeru Zakuzaku Wakame® (ふりかけるザクザクわかめ) | Crunchy wakame topping. Volumes fell in FY2026, then grew in Q1 FY2027 after TV exposure and new SKUs. | Households | — |
| Tokimeki Kaisouya (ときめき海藻屋) | Umbrella brand for seaweed products, signalling a shift from wakame to seaweed in general. | Households | 2,016 |
| Riken Non-Oil® (リケンのノンオイル) series | Oil-free dressings, the largest dressing franchise. Volumes declining after price revisions. | Households | 1989 (Aojiso Super Dressing) |
| Selecty (セレクティ) | Riken Non-Oil sub-brand. Volumes declined in Q1 FY2027. | Households | — |
| Yoshokuya-san no Tada Tada Oishii Dressing | Western-style dressing; FY2026 contributor. | Households | — |
| Fuwajiso® Aojiso & Cheese Dressing | New dressing; FY2026 contributor. | Households | FY2026 |
| Kakechae Ethnic (かけちゃえエスニック) | Non-oil dressing that turns food "ethnic" by pouring. 140,000 bottles shipped by end-April 2026; featured in Nikkei Trendy's H2 2026 break-out forecast. | Households | Feb 2026 |
| Sozairyoku Dashi® (素材力だし) | Salt-free Japanese dashi powder. FY2026 sales up on a Q3 TV campaign. | Households | 2,000 |
| Patto Jutto® (パッとジュッと) | Pouch seasoning for freezer-marinating chicken breast. Technology limits drip loss when cooked from frozen. Cumulative FY2026 shipments exceeded 500,000 pouches. | Households | Mar 2025 |
The company won the "Food Hit Award – Excellent Hit" three years running from 2022 (IR deck, Sep 2025). Specific winning SKUs are not itemised in the sources reviewed.
Domestic Food Business — Commercial Food
| Product line | Description | Target customer | Notes |
|---|---|---|---|
| Seasonings and extracts for food makers | Ramen soups, snack seasonings, onigiri wakame and other custom seasonings | Processed-food makers, convenience-store vendors | Heritage from 1963 "Riken Soup Stock" |
| Frozen seaweed | Frozen wakame, mozuku and similar; new "Frozen Mozuku Kimchi" using Okinawa Katsuren mozuku | Foodservice, catering | New demand captured in FY2026 |
| Egao de Lunch® (笑顔でランチ) series | Allergen-considerate products | School lunches; expanding to industrial catering and family restaurants | Being strengthened in FY2027 |
| CVS seaweed products | Seaweed items for convenience-store supply chains | Convenience-store vendors | Strong in FY2026 |
| Foodservice dressings and condiments | Bulk formats | Restaurants, catering | — |
Domestic Food Business — Processed Food Ingredients (food-improving agents, vitamins, colours, healthcare)
| Product line | Description and specifications | Target customer | Notes |
|---|---|---|---|
| Emulsifiers (乳化剤), including distilled monoglycerides | Improve texture, shelf life and processing. Applications span bread, noodles, tofu, Japanese and Western confectionery, beverages, processed oils, frozen foods, delicatessen, meat products and cooked rice. | Food manufacturers | Core since 1960 (Osaka); developed at the Chiba A&I Center |
| Food-loss-reduction and quality-preservation solutions | Formulations extending shelf life and replacing unstable raw materials, e.g. egg-replacement during the "egg shock" | Food manufacturers | Strategic proposal theme |
| Natural vitamin E (天然ビタミンE) | The company's "key material". Used as an antioxidant for food preservation and for nutritional fortification. | Food and supplement makers | Original vitamin heritage |
| Natural colours (天然系色素) | Gardenia yellow, gardenia blue and other plant pigments. Gardenia blue received US FDA approval as a food colour in 2025 (per LOGI-TODAY), which the company expects to drive demand. | Food and beverage makers, overseas | Made at Kyoto (Kameoka); moving to Anpachi (Gifu) by c.FY2031 |
| Crocetin (クロセチン) | Gardenia-derived carotenoid functional ingredient | Health-food makers | Launched 2006 |
| Mekabu fucoidan | Viscous polysaccharide from wakame sporophylls | Health-food makers | Launched 2006 |
| Microcapsules | Pharmaceutical and food encapsulation; solidifying flavours; stability and handling solutions | Pharma and food makers | R&D focus on functionality |
| Health-functional foods (健康機能食品) | Functional ingredient formulations for supplements and foods | Supplement and food makers | Made at Tokyo (Itabashi) |
Domestic Chemical & Other Business
| Product line | Function | End markets | Notes |
|---|---|---|---|
| Anti-fog agents (防曇剤) | Prevent condensation fogging | Food wrap, agricultural greenhouse film | Core focus area under MTP2027 |
| Anti-static agents (帯電防止剤) | Suppress static and dust attraction | Plastics, electronics packaging | Core focus area |
| Lubricants (滑剤) | Processing aids for polymers | Plastics moulding | Core focus area |
| Plasticisers (可塑剤) | Soften rigid resins | PVC, films | Core focus area |
| Bio-based / biomass additives | Plant-derived polymer additives | Environmentally conscious plastics, cosmetics | Growth theme in TCFD opportunity analysis |
| Cosmetics and toiletry additives | Emulsifiers and functional agents | Cosmetics, toiletries | Part of solution business |
| Feed oils and feed additives | Traded or manufactured feed inputs | Livestock feed | Sold via Eiken Shoji |
Overseas Business
| Product line | Producer | Sales territories | Notes |
|---|---|---|---|
| Food-improving agents (emulsifiers) | Rikevita Malaysia (core plant), Tianjin (new food-improver plant), parent exports | Global via 7 sales subsidiaries | Specialty versus commodity mix; commodity lines face price competition |
| Chemical-improving agents | Rikevita Malaysia, Tianjin (commodity chemical lines in China ended FY2026), Shanghai chemical application centre | China, Southeast Asia, global | Rationalisation under way |
| Pork and other extracts | Guymon Extracts (Oklahoma) | North America; Japan | ¥1.54 billion capacity expansion adding 500 t, completion August 2027 |
| Ramen and bakery solutions (USA) | RIKEN VITAMIN USA application centre and "Ramen Lab" | North America | Relocating to Texas; expansion planned |
| Subsidiary | Territory |
|---|---|
| Rikevita Singapore | Southeast Asia, South Asia, Oceania |
| Rikevita Viet Nam | Vietnam |
| Rikevita Thailand | Thailand |
| Riken Vitamin Europe | Europe, Africa, Middle East |
| Riken Vitamin USA | North and Latin America |
| Shanghai subsidiary | China |
| Taiwan subsidiary | Taiwan, Korea |
Sales-subsidiary territories (YUHO-FY26):
Financial Narrative
All figures are consolidated, Japanese GAAP, ¥ million unless noted.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Main products | Producing entities |
|---|---|---|---|
Domestic Food Business | Household foods; commercial foods; processed-food ingredients (raw materials, food-improving agents, vitamins) | Seaweed (wakame) products, dressings, extracts and seasonings, food-improving agents, vitamins, health-functional foods | Parent; Riken Foods (seaweed, extracts); Sunny Packaging (repacking); Eiken Shoji (distribution) |
Domestic Chemical & Other Business | Chemical-improving agents; feed additives and feed oils | Lubricants, anti-fog agents, plasticisers, anti-static agents for plastics, films, rubber and cosmetics | Parent; Kenseido (chemical additives plant); Eiken Shoji (feed trading) |
Overseas Business | Food- and chemical-improving agents, extracts, seasonings | Distilled monoglycerides and other emulsifiers, polymer additives, pork extracts | Rikevita Malaysia and Tianjin (manufacturing); Guymon Extracts (extracts); sales subsidiaries in Singapore, Vietnam, Thailand, Germany, USA, Shanghai and Taiwan |
Revenue by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Domestic Food Business (JPY Mn) | 54,130 | 58,186 | 63,154 | 64,821 | 66,360 |
Domestic Chemical & Other (JPY Mn) | 6,617 | 7,031 | 7,753 | 7,959 | 8,686 |
Overseas Business, external (JPY Mn) | 18,483 | 23,532 | 20,576 | 22,801 | 21,252 |
Consolidated net sales (JPY Mn) | 79,231 | 88,750 | 91,484 | 95,582 | 96,300 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2025–FY2026)
| Sub-segment | FY2025 | FY2026 |
|---|---|---|
Household Food (JPY Mn) | 13,586 | 13,650 |
Commercial Food (JPY Mn) | 22,755 | 23,009 |
Processed Food Ingredients (JPY Mn) | 28,480 | 29,701 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Domestic Food segment profit (JPY Mn) | 6,659 | 6,417 |
Domestic Chemical segment profit (JPY Mn) | 895 | 857 |
Overseas segment profit (JPY Mn) | 1,120 | -436 |
Adjustments (JPY Mn) | 49 | 62 |
Consolidated operating profit (JPY Mn) | 8,724 | 6,900 |
Domestic Food margin (%) | 10.3 | 9.7 |
Domestic Chemical margin (%) | 11.2 | 9.9 |
Overseas margin on gross sales (%) | 4.6 | -1.9 |
Revenue by Segment (%)
| Segment | FY2025 | FY2026 |
|---|---|---|
Domestic Food share (%) | 66.8 | 67.7 |
Domestic Chemical share (%) | 8.2 | 8.9 |
Overseas share (%) | 25.0 | 23.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Overview — Domestic Food
| Segment | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
Domestic Food (JPY Mn) | 2,040 | 1,491 | 1,550 | 1,335 |
Domestic Chemical (JPY Mn) | 270 | 200 | 204 | 181 |
Overseas (JPY Mn) | 0 | 82 | -179 | -338 |
Consolidated (JPY Mn) | 2,365 | 1,726 | 1,624 | 1,184 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 79,231 | 88,750 | 91,484 | 95,582 | 96,300 |
Gross profit (JPY Mn) | 25,564 | 27,244 | 29,886 | 31,270 | 29,767 |
SG&A (JPY Mn) | 19,723 | 20,085 | 20,514 | 22,545 | 22,866 |
Operating profit (JPY Mn) | 5,840 | 7,158 | 9,371 | 8,724 | 6,900 |
Depreciation, derived (JPY Mn) | 3,736 | 3,718 | 3,330 | 3,204 | 4,677 |
EBITDA (JPY Mn) | 9,576 | 10,876 | 12,701 | 11,928 | 11,577 |
Ordinary profit (JPY Mn) | 6,182 | 7,723 | 10,296 | 9,417 | 7,704 |
Extraordinary income (JPY Mn) | 14,343 | 194 | 2,364 | 4,503 | 2,835 |
Extraordinary losses (JPY Mn) | 213 | 60 | 751 | 1,214 | 295 |
Pre-tax income (JPY Mn) | 20,313 | 7,857 | 11,909 | 12,706 | 10,244 |
Net income attributable to owners (JPY Mn) | 21,582 | 6,414 | 8,755 | 9,388 | 7,035 |
EPS basic (JPY) | 657.98 | 195.51 | 268.44 | 310.08 | 238.19 |
EPS diluted (JPY) | 657.98 | 195.51 | 268.44 | 310.08 | 238.19 |
Dividend per share (JPY) | 46 | 59 | 81 | 94 | 110 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 32.3 | 30.7 | 32.7 | 32.7 | 30.9 |
Operating margin (%) | 7.4 | 8.1 | 10.2 | 9.1 | 7.2 |
EBITDA margin (%) | 12.1 | 12.3 | 13.9 | 12.5 | 12.0 |
Net margin (%) | 27.2 | 7.2 | 9.6 | 9.8 | 7.3 |
Net sales growth YoY (%) | 1.9 | 12.0 | 3.1 | 4.5 | 0.8 |
Operating profit growth YoY (%) | 327.2 | 22.6 | 30.9 | -6.9 | -20.9 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 102,660 | 105,223 | 118,776 | 112,999 | 116,387 |
Cash and cash equivalents (JPY Mn) | 15,064 | 16,656 | 20,141 | 18,835 | 19,131 |
Interest-bearing liabilities, company definition (JPY Mn) | 18,647 | 15,693 | 17,223 | 11,033 | 8,396 |
Net debt, negative = net cash (JPY Mn) | 3,583 | -963 | -2,918 | -7,802 | -10,735 |
Net assets (JPY Mn) | 66,539 | 71,371 | 76,643 | 79,200 | 83,379 |
Equity ratio (%) | 64.8 | 67.8 | 64.5 | 70.1 | 71.6 |
BPS (JPY) | 2,027.84 | 2,174.39 | 2,523.84 | 2,649.95 | 2,855.29 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2025 | FY2026 |
|---|---|---|
Short-term borrowings incl. current portion of LT debt (JPY Mn) | 3,373 | 1,941 |
Long-term borrowings (JPY Mn) | 6,541 | 5,200 |
Goodwill and intangibles (JPY Mn) | 980 | 1,011 |
Investment securities (JPY Mn) | 15,078 | 15,025 |
Current assets (JPY Mn) | 65,699 | 66,227 |
Current liabilities (JPY Mn) | 21,129 | 19,434 |
Working capital (JPY Mn) | 44,570 | 46,793 |
Inventories (JPY Mn) | 19,610 | 22,061 |
Asset retirement obligations (JPY Mn) | 610 | 2,204 |
Retirement benefit asset (JPY Mn) | 4,104 | 4,784 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 6,823 | 7,835 | 10,451 | 7,892 | 5,963 |
Investing cash flow (JPY Mn) | -3,661 | -2,034 | -554 | 353 | 1,747 |
Financing cash flow (JPY Mn) | -7,565 | -4,578 | -7,084 | -9,965 | -8,040 |
Capex, PP&E purchases (JPY Mn) | 3,250 | 2,112 | 2,536 | 4,678 | 4,863 |
FCF, OCF minus capex (JPY Mn) | 3,573 | 5,723 | 7,915 | 3,214 | 1,100 |
FCF, company definition OCF+ICF (JPY Mn) | 3,162 | 5,801 | 9,897 | 8,245 | 7,711 |
Dividends & Capital Returns
| Item | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Dividends paid (JPY Mn) | — | 2,776 | 3,242 |
Treasury share purchases (JPY Mn) | ≈6,360 (Kikkoman block, Feb 2024; MTP2027 cites ¥6.3 billion) | 1,133 | 2,000 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 38.3 | 9.3 | 11.8 | 12.1 | 8.7 |
ROA, net income / total assets (%) | 21.0 | 6.1 | 7.4 | 8.3 | 6.0 |
Interest coverage, OCF / interest paid (x) | 24.9 | 61.3 | 92.2 | 69.2 | 51.7 |
Payout ratio, consolidated (%) | 7.0 | 30.2 | 30.2 | 30.3 | 46.2 |
PER at fiscal year-end (x) | 2.5 | 9.8 | 9.6 | 7.8 | 12.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x) (FY2025–FY2026)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROIC, NOPAT at 30% tax / (equity + debt − cash) (%) | 8.6 | 6.7 |
Current ratio (x) | 3.11 | 3.41 |
Debt / equity, company-defined debt (x) | 0.14 | 0.10 |
Net debt / EBITDA (x) | -0.65 | -0.93 |
Operating profit / interest expense (x) | 70.9 | 60.5 |
Asset turnover, sales / average total assets (x) | 0.82 | 0.84 |
DSO (days) | 83 | 86 |
DIO, on cost of sales (days) | 111 | 121 |
DPO, on cost of sales (days) | 45 | 43 |
Cash conversion cycle (days) | 150 | 164 |
Revenue by Region and Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Japan (JPY Mn) | 61,367 | 61,002 | 65,220 | 70,908 | 72,786 |
Other / overseas (JPY Mn) | 16,354 | 18,228 | 23,530 | 20,575 | 22,796 |
Overseas share of sales (%) | 21.0 | 23.0 | 26.5 | 22.5 | 23.8 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Japan growth (%) | -0.6 | 6.9 | 8.7 | 2.6 |
Other / overseas growth (%) | 11.5 | 29.1 | -12.6 | 10.8 |
Geographic Revenue
| Region | FY2026 performance | Q1 FY2027 performance (SUPP-1Q27) |
|---|---|---|
North America | Sales up; major-customer adoption from Q2; extract growth. The fastest-growing region. | Sales up; improver sales to major customers expanding; extracts strong; US tariff refund recognised |
Taiwan | Sales up; the only region with volume growth | Sales up |
China | Volume decline continued on sluggish consumption | Food-improver volumes above prior year as recovery measures take effect |
Southeast Asia | Volume decline; intensified price competition in general-purpose products | Sales up (FX and volume) |
Europe | Volume decline; price competition | Sales up (FX and volume) |
Share Price
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price high (JPY) | 1,978 | 2,089 | 2,626 | 2,879 | 3,285 |
Share price low (JPY) | 1,337 | 1,574 | 1,900 | 2,300 | 2,204 |
Riken Vitamin TSR index | 126.2 | 148.6 | 202.5 | 197.7 | 239.0 |
TOPIX incl. dividends index | 102.0 | 107.9 | 152.5 | 150.2 | 202.2 |
Valuation Multiples
| Multiple | Riken Vitamin | Prime-food median (COC-2026, Mar 2026) |
|---|---|---|
P/E trailing (FY2026 EPS ¥238.19) | 14.0x | about 14x |
P/E forward (FY2027 guidance EPS ¥256.96) | 12.9x | — |
P/B (FY2026 BPS ¥2,855.29) | 1.16x (kabuyoho 1.14x on Q1 BPS) | about 1.3x |
EV/EBITDA (FY2026) | ≈7.2x | — |
EV/Sales (FY2026) | ≈0.87x | — |
Dividend yield (FY2027 DPS ¥110) | 3.31% | — |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Annual DPS (JPY) | 46 | 59 | 81 | 94 | 110 |
Interim DPS (JPY) | 21 | 23 | 30.5 | 40.5 | 55 |
Consolidated payout ratio (%) | 7.0 | 30.2 | 30.2 | 30.3 | 46.2 |
Capital Programmes
| Programme | Shares | Amount | Status |
|---|---|---|---|
2016 self-TOB | 6.6 million (pre-split) | ≈¥24.4 billion | Completed |
Feb 2024 ToSTNeT-3 (Kikkoman) | 2,473,900 | ¥6.36 billion | Completed |
Feb 2025 ToSTNeT-3 | 487,100 | ¥1.13 billion | Completed |
May 2025 – Mar 2026 market purchases | 696,500 | ¥2.00 billion | Completed |
Jun – Sep 2026 market purchases (cap 900,000 / ¥2.0 billion) | 522,600 at 31 Aug | ¥1.63 billion at 31 Aug | Expired 30 Sep 2026; final result pending disclosure |
Cancellations | 7,000,000 (May 2022); 3,000,000 (Mar 2025) | — | — |
Bucket Details
| Bucket | JPY Mn |
|---|---|
Within 1 year (short-term ¥600 plus current long-term ¥1,341) | 1,941 |
1–2 years | 5,141 |
2–3 years | 59 |
Beyond 3 years | 0 |
Total borrowings | 7,141 |
Analyst Conclusions
Guidance and expectations
Company guidance for FY2027 (unchanged at Q1): sales ¥100.0 billion (+3.8%), OP ¥7.1 billion (+2.9%), NP ¥7.5 billion (+6.6%), DPS ¥110, ROE 9.0%. Guidance embeds:
-
an Overseas full-year loss of ¥200 million, despite a Q1 profit of ¥151 million;
-
continuing asbestos charges (Q1: ¥187 million);
-
labour-cost inflation (+¥470 million in Q1);
-
FX of about ¥150/$, versus a Q1 average of ¥160/$.
Q1 progress: OP ¥2.25 billion is 31.7% of the full-year plan and ordinary profit is 33.5%. The company typically front-loads profit in Q1 (FY2026 Q1 was 34% of full-year OP), so the progress rate alone does not signal a beat.
Consensus expects ordinary profit of about ¥8.7 billion, implying the market sees the guidance as conservative. Investors cite "conservative guidance" as one reason for the discount (COC-2026).
Bull case
-
Overseas inflection is real. Q1 FY2027 overseas sales rose 18.3%, with a return to profit in all regions on volume recovery, North American adoption and China food-improver recovery. Guymon capacity (+500 t, Aug 2027) and US natural-colour demand add structural growth. A move from −¥436 million toward the ¥1.6 billion FY2028 target could add more than ¥2 billion to operating profit.
-
Capital efficiency has a long runway. Equity ratio 71.6% versus a 60–65% target; cross-holdings of ¥15.0 billion (17.9% of net assets) versus a target below 10%; net cash. The 40%+ payout plus recurring ¥2 billion buybacks (about 2% of market cap a year) supports a total yield above 5% and steady EPS accretion. EPS rose 2.5x in ten years while the share price rose only 1.4x (COC-2026).
-
Normalised margin recovery. The FY2026 operating margin of 7.2% included about 90 bp of one-off asbestos charges. As depreciation steps plateau and price revisions catch up, a return toward the 9–10% achieved in FY2024–FY2025 would imply ¥9–10 billion of OP on ¥100 billion of sales. Applying a 14x sector-median P/E to the resulting EPS would justify a materially higher price.
Bear case
-
Structural margin squeeze. Wage inflation (5.5% parent base-up), depreciation up 46%, and recurring asbestos charges against a stagnant domestic volume base suggest the FY2024 margin peak was cyclical. The MTP2027 target of ¥10 billion OP is already out of reach on guidance (¥7.1 billion).
-
Earnings quality and cash conversion. About a third of pre-tax profit comes from selling cross-shareholdings, a finite source. OCF-minus-capex FCF was only ¥1.1 billion in FY2026, and ¥25 billion of capex (including the ¥3.6 billion Anpachi land before construction cost) will keep FCF thin through FY2028, potentially forcing reliance on balance-sheet cash to fund returns.
-
Overseas commoditisation and geopolitics. General-purpose emulsifiers face price competition in Europe and Southeast Asia. China remains fragile. US tariff policy is unpredictable: Q1's tariff refund flatters results, while Malaysia-to-US flows remain exposed. The FY2027 guidance itself assumes an overseas loss.
Catalysts and monitorables (next 12 months)
| Timing | Item | What to watch |
|---|---|---|
| Early Oct 2026 | Final buyback tally (Jun–Sep programme) | Completion versus ¥2.0 billion cap |
| Mid-Nov 2026 | H1 FY2027 results | Overseas profitability persistence; asbestos run-rate; any guidance revision versus consensus ¥8.7 billion ordinary profit |
| Late Oct / Nov 2026 | Interim dividend | ¥55 confirmed |
| Feb 2027 | Q3 FY2027 | North America and China trends; Q3 has historically disappointed (Feb 2026 shares fell 6.6% on results) |
| May 2027 | FY2027 results, FY2028 guidance, new buyback | Whether management reaffirms or resets MTP2027 targets; payout and buyback for the plan's final year |
| Aug 2027 | Guymon expansion completion | Utilisation ramp |
| Autumn 2027 | Anpachi land title transfer; plant capex disclosure | Total project cost and return on investment |
| Ongoing | Cross-shareholding sales | Progress from 17.9% toward below 10% of net assets |
| Ongoing | US tariffs, palm and vegetable-oil prices, JPY/USD | Earnings sensitivity |
| Ongoing | Riken Non-Oil volume trend; 50th-anniversary wakame campaign | Household franchise health |
Analyst verdict
Riken Vitamin is a well-capitalised, technology-rich but under-earning mid-cap. It has spent the five years since the 2020 Qingdao scandal rebuilding credibility, and has largely succeeded in governance and capital-markets terms:
-
the Kikkoman overhang is gone;
-
cross-holdings are falling;
-
payout has risen from 30% to over 40%;
-
buybacks are now annual;
-
the stock has crossed the company's own "first milestone" of a ¥100 billion market capitalisation.
Five-year TSR has beaten TOPIX.
The operating story has gone backwards since FY2024. Operating profit fell 26% over two years. The first year of MTP2027 missed every financial target. Overseas, meant to be the growth engine toward a 35% sales share, swung to a loss. Meanwhile depreciation, wages and legacy asbestos liabilities are rising, and the ¥25 billion capex programme has yet to show returns. Reported net profit has been propped up by one-off securities gains, and true free cash flow has thinned sharply.
The Q1 FY2027 overseas turnaround is the most important recent data point. It should not be over-read: management still guides to an overseas loss for the year, and part of the improvement was a tariff refund.
On balance, the shares at about 12.9x forward earnings, about 1.15x book and a 3.3% yield are fairly valued for a low-growth, high-return-of-capital profile. They offer asymmetric upside only if overseas profitability proves durable. Key confirmation points are H1 FY2027 (November 2026) and the FY2028 guidance in May 2027.
Downside appears cushioned by net cash, about ¥15 billion of saleable securities, and a committed payout floor. The more likely path is a gradual re-rating toward sector multiples as capital is returned, rather than a growth-led re-rating. MTP2027's ¥10 billion operating-profit goal should be treated as aspirational. Investors should anchor on about ¥7–8.5 billion of operating profit for FY2027, the range between company guidance and implied consensus.
Stance: Neutral, with a positive bias contingent on overseas delivery.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title / responsibilities | Born | Background | Shares held (000) |
|---|---|---|---|---|
Kazuhiko Yamaki (山木一彦) | Chairman of the Board | Feb 1959 | Joined 1983; commercial-foods sales chief; Director 2010; President June 2016 – June 2025 (steered the post-scandal recovery) | 16 |
Tsutomu Mochizuki (望月敦) | Representative Director & President (from June 2025) | Mar 1962 | Joined 1985 (Tokyo University of Fisheries graduate); President of Riken Vitamin Europe GmbH (2004); head of International Business; 2nd Production Division; Executive Officer 2014; Director 2022; Managing Director 2023 | 7 |
Nobuo Dotsu (道津信夫) | Representative Director, Senior Managing; administration (compliance, GA, HR), business strategy | Aug 1960 | Joined 1985; head of food-improver development; Executive Officer 2014 | 6 |
Takahiro Tomitori (冨取隆浩) | Managing Director; sustainability, accounting, systems, corporate strategy; GM Corporate Planning (from April 2026) | Aug 1965 | Ex-Dai-Ichi Kangyo / Mizuho Bank (Executive Officer, Fukuoka branch GM); Mizuho Research Institute; joined 2021 | 2 |
Masaaki Nakano (中野正明) | Director; food-improver business, international business, chemical business | Jan 1965 | Joined 1987; processed-food sales; global marketing; Executive Officer 2020 | 5 |
Takumi Aoki (青木巧) | Director (new, June 2026); food business, healthcare business | Mar 1966 | Joined 1988; branch manager; commercial-foods sales chief; Executive Officer 2019 | 3 |
Shinichi Hirano (平野伸一) | Independent Outside Director | Jan 1956 | Former President of Asahi Breweries (2016); outside director at Gig Works and Shinko Kogyo | 2 |
Takehiko Makinodan (牧之段武彦) | Director, Full-time Audit & Supervisory Committee Member | Oct 1962 | Joined 1986; Chiba plant manager; head of production; head of quality assurance | 10 |
Satoshi Fujinaga (藤永敏) | Independent Outside Director, Full-time A&SC Member; chairs Nomination and Remuneration Committees | Sep 1959 | Ex-Takeda Pharmaceutical (Asia-Pacific VP); pharmacist; outside auditor from 2015 | 5 |
Nagahisa Sueyoshi (末吉永久; registered name 權正永久) | Independent Outside Director, A&SC Member | Apr 1968 | Attorney (Mukai Law Office); former civil conciliation officer | 4 |
Wataru Sueyoshi (末吉亙) | Independent Outside Director, A&SC Member | Oct 1956 | Attorney (KTS Law Office; ex-Mori Hamada & Matsumoto); outside director at Mitsubishi Estate | 0 |
Ayumi Ujihara (氏原亜由美) | Independent Outside Director, A&SC Member | Sep 1961 | CPA; ex-PwC Aarata partner; outside auditor at Yamaha Motor; outside director at Makita | 0 |
Directors' Remuneration
| Category | Headcount | Total (JPY Mn) | Fixed | Bonus | Performance share (non-cash) |
|---|---|---|---|---|---|
Directors excluding A&SC members and outside directors | 6 | 223 | 165 | 47 | 10 |
A&SC member directors (internal) | 2 | 17 | 17 | — | — |
Outside directors | 5 | 60 | 60 | — | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jun 2016 | Yamaki appointed President | Succeeded Miho Sakai |
Nov 2020 | Management-responsibility measures after Qingdao scandal | TDnet 19 Nov 2020 |
Jun 2021 | Tomitori (ex-Mizuho) and Hirano (ex-Asahi) join the board | Post-scandal governance reinforcement |
Jun 2023 | Ujihara (CPA) joins as A&SC member; second woman on board | — |
Jun 2025 | Mochizuki becomes President; Yamaki becomes Chairman | Announced 30 Apr 2025, to run MTP2027 with new leadership. Mochizuki's international background aligns with the overseas-growth emphasis. |
Jun 2026 | Takahisa Nakano (Rep. Senior Managing) retires from board; Aoki joins | AGM 23 Jun 2026 |
Major Shareholders
| Rank | Holder | Shares (000) | % |
|---|---|---|---|
| 1 | Riken Vitamin Business Partners' Shareholding Association | 3,351 | 11.40 |
| 2 | Master Trust Bank of Japan (trust account) | 1,803 | 6.13 |
| 3 | Master Trust Bank of Japan (retirement benefit trust, Miyoshi Oil & Fat) | 1,080 | 3.67 |
| 4 | Riken Vitamin Employee Shareholding Association | 772 | 2.62 |
| 5 | Sumitomo Life Insurance | 726 | 2.47 |
| 6 | Mizuho Bank (via retirement benefit trust) | 693 | 2.36 |
| 7 | Asahi Mutual Life Insurance | 438 | 1.49 |
| 8 | Custody Bank of Japan (trust account) | 425 | 1.44 |
| 9 | Shimizu Foods (清水食品) | 355 | 1.21 |
| 10 | Mitsubishi UFJ Trust & Banking | 336 | 1.14 |
| — | Top 10 total | 9,982 | 33.98 |
Major Shareholders by Holder Type
| Holder type | % |
|---|---|
Individuals and others | 46.01 |
Financial institutions | 21.63 |
Other corporations | 19.50 |
Foreign | 11.52 |
Securities firms | 1.33 |
Competitive Landscape
Competitors by Segment
| Segment / category | Key competitors | Notes on relative positioning |
|---|---|---|
Household dressings | Kewpie (2809); Mizkan (private); Nisshin OilliO (2602); Ajinomoto (2802) | Kewpie is the dominant mayonnaise and dressing player: FY11/2025 sales ¥513.4 billion, OP ¥34.6 billion (Kewpie tanshin, 14 Jan 2026). Riken is the oil-free specialist. |
Dried wakame and wakame soup | Various seaweed processors and private brands; instant-soup makers (e.g. Nagatanien, Ajinomoto) | Riken claims No.1 share in domestic dried cut wakame and instant wakame soup (IR deck Jan 2026); share percentage not disclosed |
Dashi / seasonings | Ajinomoto (Hondashi); Yamaki (private); Shimaya (private); Kikkoman | Riken is niche (salt-free "Sozairyoku"); share not disclosed |
Food emulsifiers (Japan) | Taiyo Kagaku (2902); Mitsubishi Chemical (sugar esters); Sakamoto Yakuhin Kogyo (polyglycerol esters); Kao | Taiyo Kagaku FY3/2026: sales ¥52.5 billion, OP ¥7.1 billion (13.5% margin) (Taiyo Kagaku tanshin, 11 May 2026) |
Food emulsifiers (global) | IFF (ex-DuPont/Danisco), Palsgaard (private, Denmark), Kerry, Corbion, BASF, Chinese producers | Riken is a mid-sized Asian-based distilled-monoglyceride producer, exposed to commodity price competition per FY2026 commentary. |
Natural colours | San-Ei Gen F.F.I. (private), Oterra (private), Givaudan Sense Colour, Sensient | Riken is strong in gardenia colours; gardenia blue is an opportunity after the FDA decision |
Natural vitamin E | DSM-Firmenich, BASF, Eisai Food & Chemical, ADM, Chinese producers | Riken positions natural vitamin E as a "key material" |
Polymer additives | ADEKA (4401), Kao, Sakamoto Yakuhin, Riken Technos (compounder, not a direct rival), global additive majors | Riken holds ADEKA shares (¥1.17 billion), a cross-holding with a business partner and competitor |
Pork extracts (US) | US flavour and extract houses (e.g. | Guymon is a niche producer |
Peer Comparison FY2011
| Metric | Riken Vitamin (FY3/2026) | Taiyo Kagaku (FY3/2026) | Kewpie (FY11/2025) |
|---|---|---|---|
Net sales | ¥96.3bn | ¥52.5bn | ¥513.4bn |
Sales growth | +0.8% | +4.9% | +6.1% |
Operating profit | ¥6.9bn | ¥7.1bn | ¥34.6bn |
Operating margin | 7.2% | 13.5% | 6.7% |
ROE | 8.7% | 9.9% | 9.7% |
Equity ratio | 71.6% | 79.4% | 67.4% |
R&D intensity | 4.1% | — | — |
Recent Developments
--



